Weifa ASA to launch Solvivo® - a new OTC product for sore throat in Norway.

Weifa ASA is pleased to announce the launch of Solvivo® lozenges.

With Solvivo® Weifa enters the OTC throat segment, which has had a value growth of 64% last twelve months¹, and represents a value of MNOK 11 last twelve months² (pharmacy purchasing price). This is the fastest growing segment within the Cough & Cold³ category.

“Solvivo® is a strong fit with Weifa`s product portfolio, as well as the company`s ambitious strategy for the Cough and Cold category”, says CEO Kathrine Gamborg Andreassen. “The launch is set to strengthen Weifa`s current position as the fastest growing player within Cough & Cold.”

The launch will be supported by a solid communications campaign towards the end user, as well as a strong effort in training pharmacy staff.

Solvivo® is indicated for local symptomatic relief of mild mouth and throat infections in adults and children aged over 6 years. It contains the two active substances amylmetacresol and dichlorobenzyl alcohol, which have antiseptic properties. The product also provides a relieving effect on a sore throat and on difficulty in swallowing.

Similar products associated with strong commercial success can be found in many other countries; however, there are no identical products to Solvivo® on the Norwegian market.

Solvivo® comes in packs of 24 lozenges, in flavours of Honey & Lemon and Mint. It will be available through all pharmacy chains from September 15^th 2016.

For further information, please contact:

Kathrine Gamborg Andreassen

CEO

+47 95 17 86 80, kathrine.gamborg.andreassen@weifa.no

Simen Nyberg-Hansen

CFO

+47 98 20 63 55, simen.nyberg-hansen@weifa.no

Ref: 1,2,3,4: Farmastat September, 2016.

Barn under 6 år skal ikke ta dette legemidlet. Kontakt lege dersom symptomene ikke bedres innen 2 dager. Skal ikke brukes under graviditet og amming. Les pakningsvedlegget nøye før bruk.